Published in TB and Outbreaks Week, April 23rd, 2002
The inventory is estimated to be between 75 and 90 million doses with the exact amount to be confirmed by clinical studies. The vaccine comes from the company's existing stock and has an estimated commercial value in excess of $150 million. It will provide a short-term safety stock for emergency use during this period of time in which the U.S. may be particularly vulnerable to a terrorist smallpox attack until new vaccine supplies are available.
The company has worked...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.